Current guidelines suggest treatment with corticosteroids (CS) in IgA nephropathy (IgAN) when proteinuria is persistently ≥1 g/d despite 3-6 months of supportive care and when eGFR is >50 ml/min per 1.73 m2.Whether the benefits of this treatment extend to patients with an eGFR ≤50 ml/min per 1.73 m2, other levels of proteinuria, or different renal pathologic lesions remains unknown. We retrospectively studied 1147 patients with IgAN from the European Validation Study of the Oxford Classification of IgAN (VALIGA) cohort classified according to the Oxford-MEST classification and medication used, with details of duration but not dosing. Overall, 46% of patients received immunosuppression, of which 98% received CS. Treated individuals presented with greater clinical and pathologic risk factors of progression. They also received more antihypertensive medication, and a greater proportion received renin angiotensin system blockade (RASB) compared with individuals without immunosuppressive therapy. Immunosuppression was associated with a significant reduction in proteinuria, a slower rate of renal function decline, and greater renal survival. Using a propensity score, we matched 184 subjects who received CS and RASB to 184 patients with a similar risk profile of progression who received only RASB. Within this group, CS reduced proteinuria and the rate of renal function decline and increased renal survival. These benefits extended to those with an eGFR#50 ml/min per 1.73 m2, and the benefits increased proportionally with the level of proteinuria. Thus, CS reduced the risk of progression regardless of initial eGFR and in direct proportion to the extent of proteinuria in this cohort.

Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA study / Vladimir, Tesar; Stéphan, Troyanov; Shubha, Bellur; Jacobien C., Verhave; H., Terence Cook; John, Feehally; Ian S. D., Roberts; Daniel, Cattran; Rosanna, Coppo; on behalf of the VALIGA study of the ERA EDTA Immunonephrology Working, Group; Magistroni, Riccardo. - In: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. - ISSN 1046-6673. - STAMPA. - 26:9(2015), pp. 2248-2258. [10.1681/ASN.2014070697]

Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA study

MAGISTRONI, Riccardo
2015

Abstract

Current guidelines suggest treatment with corticosteroids (CS) in IgA nephropathy (IgAN) when proteinuria is persistently ≥1 g/d despite 3-6 months of supportive care and when eGFR is >50 ml/min per 1.73 m2.Whether the benefits of this treatment extend to patients with an eGFR ≤50 ml/min per 1.73 m2, other levels of proteinuria, or different renal pathologic lesions remains unknown. We retrospectively studied 1147 patients with IgAN from the European Validation Study of the Oxford Classification of IgAN (VALIGA) cohort classified according to the Oxford-MEST classification and medication used, with details of duration but not dosing. Overall, 46% of patients received immunosuppression, of which 98% received CS. Treated individuals presented with greater clinical and pathologic risk factors of progression. They also received more antihypertensive medication, and a greater proportion received renin angiotensin system blockade (RASB) compared with individuals without immunosuppressive therapy. Immunosuppression was associated with a significant reduction in proteinuria, a slower rate of renal function decline, and greater renal survival. Using a propensity score, we matched 184 subjects who received CS and RASB to 184 patients with a similar risk profile of progression who received only RASB. Within this group, CS reduced proteinuria and the rate of renal function decline and increased renal survival. These benefits extended to those with an eGFR#50 ml/min per 1.73 m2, and the benefits increased proportionally with the level of proteinuria. Thus, CS reduced the risk of progression regardless of initial eGFR and in direct proportion to the extent of proteinuria in this cohort.
2015
12-feb-2015
26
9
2248
2258
Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA study / Vladimir, Tesar; Stéphan, Troyanov; Shubha, Bellur; Jacobien C., Verhave; H., Terence Cook; John, Feehally; Ian S. D., Roberts; Daniel, Cattran; Rosanna, Coppo; on behalf of the VALIGA study of the ERA EDTA Immunonephrology Working, Group; Magistroni, Riccardo. - In: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. - ISSN 1046-6673. - STAMPA. - 26:9(2015), pp. 2248-2258. [10.1681/ASN.2014070697]
Vladimir, Tesar; Stéphan, Troyanov; Shubha, Bellur; Jacobien C., Verhave; H., Terence Cook; John, Feehally; Ian S. D., Roberts; Daniel, Cattran; Rosan...espandi
File in questo prodotto:
File Dimensione Formato  
Tesar-2015-Corticosteroids in I.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 792.96 kB
Formato Adobe PDF
792.96 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1116600
Citazioni
  • ???jsp.display-item.citation.pmc??? 56
  • Scopus 180
  • ???jsp.display-item.citation.isi??? 168
social impact